MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'hiv vaccine'. Sat, 03 Sep 2011 02:59:33 +0100 http://www.medworm.com/index.php?rid=4775399&cid=t_149552_87_f&fid=39261&url=http%3A%2F%2Fvactruth.com%2F2011%2F05%2F02%2Fhivaids-in-africa-caused-through-doctors-vaccinating-with-contaminated-needles%2F In 1998 the San Francisco Chronicle published an article by Reynolds Holding and William Carlsen entitled ‘DEADLY NEEDLES Fast Track to Global Disaster’. The article describes how children in Nairobi were combing through piles of rubbish in search of used hypodermic syringes to sell to private clinics in Kenya and India. A photo of a small child surrounded by filth and squalor holding a used syringe, complete with needle, to sell to private clinics is the powerful image used for the piece. The caption reads: “Nairobi child scavenges for used syringes. Private clinics sometimes buy them. “It’s a big secret,” said trash worker Jeremiah Musyimi.“ The authors reported news of an internal World Health Organization study which had revealed that every year as... vactruth.com blogs http://www.medworm.com/rss/comments.php?id=4775399 Mon, 02 May 2011 14:32:26 +0100 4775399 http://www.medworm.com/index.php?rid=1883572&cid=t_149552_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F421525708%2F A US recession could cut AIDS funding and impede the drive to find a vaccine for the disease, according to a senior official with Global HIV Vaccine Enterprise. The US is the center of AIDS vaccine research and contributed $659 million, or 69 percent of the funds earmarked for research in 2007, according to data released at a global AIDS vaccine conference in Cape Town, South Africa. But a credit crunch has raised fears that the US government and the private sector will cut funding to a broad range of programs, including AIDS research. “If there is a downturn in the economy it’s going to potentially have a negative impact on funding for science in general and HIV vaccine research in particular,” Alan Bernstein, executive director of the Global HIV Vaccine Enterprise, told... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1883572 Wed, 15 Oct 2008 10:39:51 +0100 1883572 http://www.medworm.com/index.php?rid=1024395&cid=t_149552_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F184349059%2F The idea is to tell the 3,000 volunteers so they know whether to pursue HIV testing. You may recall that, shortly after Merck halted its HIV vaccine, the drugmaker acknowledged the experimental med may have compromised patient immune systems, making those who were vaccinated more vulnerable to the risk of infection. The move was made after a conference last week with its partners, the NIH and the HIV Vaccine Trials Network. However, the move raises a potentially different set of problems. As Merck’s statement this afternoon makes clear, the researchers still intend to continue following the trial participants to gauge infection rates. But the behavior of the trial participants may very well change after knowing whether they were vaccinated or given a placebo. This, obviously, could m... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1024395 Tue, 13 Nov 2007 22:37:39 +0100 1024395 http://www.medworm.com/index.php?rid=1018997&cid=t_149552_107_f&fid=36585&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FHighlightHealth%2F%7E3%2F182859698%2F Conclusion that Discarded Merck Vaccine Candidate is Ineffective. International AIDS Vaccine Initiative. 2007 Nov 7. ad5, hiv, hiv vaccine, hiv virus, merck, STEP, vaccineBookmark or Share Thank you for subscribing by email / RSS. I work hard to make the articles on Highlight HEALTH engaging and I truly appreciate your interest! This article was published on Highlight HEALTH. (Source: Highlight HEALTH) Highlight HEALTH blogs http://www.medworm.com/rss/comments.php?id=1018997 Sat, 10 Nov 2007 23:05:51 +0100 1018997 http://www.medworm.com/index.php?rid=1012484&cid=t_149552_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F181264814%2F Two weeks ago, we wrote that Merck’s failed HIV vaccine may have actually caused some clinical trial participants to become infected, and the 3,000 volunteers should be tested. As it turns out, a subset of patients developed the virus at a higher rate than those given a placebo, and all of them were HIV-negative at the start of the trial. Most likely, the vaccine made the body’s immune system more vulnerable. For a vaccine that was tested for prevention, this is a cruel irony. And the numbers are sobering. Overall, as of mid-October there were 49 cases of HIV infection among the 914 male volunteers in the vaccine group, compared with 33 cases among the 922 males in the placebo group, according to a Merck statement. The participants who were more suspectible began the study wit... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1012484 Wed, 07 Nov 2007 20:33:43 +0100 1012484 http://www.medworm.com/index.php?rid=918023&cid=t_149552_87_f&fid=35060&url=http%3A%2F%2Fwww.healthnewsblog.com%2Fcgi-bin%2Fhnblog.pl%3Fhnblog%3D924071 There was some very unfortunate news earlier this week when Merck reported that it was halting its AIDS vaccine test because tests showed the vaccine was not working - people were still getting infected with the HIV virus. Merck & Co. said Friday that it is ending enrollment and vaccination of volunteers in the study, which was partly funded by the National Institutes of Health. It was a high-profile failure in the daunting quest to develop a vaccine to prevent AIDS. Merck's vaccine was the farthest along, considered the most promising and was closely watched by experts in the field. The test was an obvious failure because more people who received the vaccine later became HIV positive than those who received dummy shots. Officials at the company, based in Whitehouse Station, N.J., sa... HealthNewsBlog.com blogs http://www.medworm.com/rss/comments.php?id=918023 Tue, 25 Sep 2007 03:00:00 +0100 918023 http://www.medworm.com/index.php?rid=891919&cid=t_149552_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F159571665%2F This is a big blow to the drugmaker, which has been chasing an HIV vaccine for two decades and regularly boasted of its commitment to combating AIDS. But the trial was ended after an independent safety monitoring board decided the vaccine was ineffective and would fail to meet mid-stage trial goals. The study was designed to determine whether the vaccine prevented HIV and reduced the amount of virus in those who developed infection. “We share in the disappointment of the research and HIV communities today. Sadly, developing an effective AIDS vaccine remains one of the most challenging tasks facing modern medicine,” says Peter Kim, Merck’s chief scientist, in a statement. Adds Glenda Gray, the principal investigator of the trial, which was sponsored by the HIV Vaccine Tria... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=891919 Fri, 21 Sep 2007 18:04:54 +0100 891919